A study led by Aaron Hobbs, Ph.D., and Rachel Burge, Ph.D., at MUSC Hollings Cancer Center, reveals why a specific gene ...

A research team at the Medical University of Vienna has discovered a new approach to treating a particularly frequent and ...

The deadliest cancers just met their match. A revolutionary cancer vaccine prevents the devastating relapses that have made KRAS-mutated tumors nearly impossible to cure, offering genuine hope to ...

Responsible for nearly 10 million deaths worldwide in 2020, cancer consistently ranks among the leading causes of death each year. Brought on by genetic mutations and external risk factors, cancer is ...

Mutations in the KRAS gene are the primary driver of pancreatic cancer. A new class of drugs known as KRAS inhibitors is showing initial promise in clinical trials, but many tumors quickly develop ...

Knowable Magazine reports on advancements in pancreatic cancer treatment, including new drugs, vaccines, and early diagnostic ...

The University of Cincinnati Cancer Center’s Tom Cunningham has received a two-year, $150,000 grant from the Lung Cancer Research Foundation (LCRF) to test approaches to neutralize an enzyme complex ...

Blood-based circulating tumor DNA (ctDNA) testing has proven to be insufficient for detecting KRAS mutations in patients with low-grade serous ovarian cancer (LGSOC), according to a study. The ...

New data in human cancer cell lines provides confirmation of pan-KRAS mutation inhibition with inhibition of G12D, G12V, G12R, G12C, G13C, G12A, Q61H, and G13D mutations Company Reports first evidence ...

The drug is not considered a cure, but results emerging from clinical trials point to the first major advancement in decades for a devastating cancer.

Even after surgery and chemotherapy, some cancers, like pancreatic and colorectal, maintain a foothold in the body and ...